Genentech/Xoma revise Xanelim filing date
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech and Xoma anticipate submitting a Xanelim (efalizumab) BLA for psoriasis treatment in summer 2002. The companies had predicted a year-end or first quarter 2002 submission, but FDA requested a pharmacokinetic study to confirm equivalence between the drug formulation used in clinical trials and that planned for large-scale manufacture